drugset / Trial / NCT06063850
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
NaSequentialOpen-labelTreatment
Summary
The main goals of this clinical study are to learn if AMT-260 is safe and tolerable and works to reduce the frequency of seizures in adults with unilateral mesial temporal lobe epilepsy (MTLE).
Timeline
- Start
- 2024-06-12
- Primary completion
- 2026-11-30
- Completion
- 2031-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AAV9-hSyn1-miGRIK2 | Unknown | 6e+11 unknown | Other |
| Subject | AAV9-hSyn1-miGRIK2 | Unknown | 1e+12 unknown | Other |
| Subject | AAV9-hSyn1-miGRIK2 | Unknown | 3e+12 unknown | Other |